Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT05393466 is registered in ClinicalTrials.gov with Xcovery Holdings, Inc. as lead sponsor.

NCT NCT05393466
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05393466 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Xcovery Holdings, Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
May 31, 2029
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma